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Background: Polycystic ovary syndrome (PCOS) has been recognized as a metabolic disorder, manifested by
abdominal obesity, insulin resistance, dyslipidemia and hypertension. Pigment epithelium-derived factor (PEDF), a
member of the serine protease inhibitor family, is a pleiotropic protein known for its antiangiogenic, antioxidant,
and neuroprotective properties and has been shown to induce insulin resistance and play a role in glucose
metabolism. Recent studies investigating circulating PEDF levels show elevated serum PEDF in association with
insulin resistance in normal-weight women with PCOS, but not in obese PCOS patients. The aims of this study were
1) to assess PEDF gene expression in subcutaneous adipose tissue (scAT) from women with PCOS and nonhirsute,
ovulatory controls, and 2) to determine the circulating levels of PEDF in these groups.
Methods: Total RNA was extracted from adipose tissue biopsy samples and reverse-transcribed to cDNA. Real-time
quantitative PCR was performed to determine relative gene expression levels.
Results: The 22 women with PCOS and 14 non-PCOS controls included in the study had similar age, BMI, and
fasting glucose, triglycerides, and HDL-cholesterol levels. Participants with PCOS exhibited higher 2 h oral glucose
tolerance test levels (p = 0.006), total (p = 0.026) and LDL-cholesterol (p = 0.036), Ferriman-Gallwey score (p = 0.003)
and total testosterone (p = 0.001) as compared to controls. BMI-adjusted PEDF serum levels and scAT gene
expression were similar in the PCOS and control groups (p = 0.622 and p = 0.509, respectively). Circulating PEDF
levels were not associated with scAT PEDF gene expression. Multiple regression analysis revealed that, in women
with PCOS, insulin contributed positively and significantly to serum PEDF (p = 0.027), independently of testosterone.
Conclusion: Serum PEDF levels and scAT gene expression were associated with metabolic risk factors, but did not
differ between women with PCOS and age- and BMI-matched controls. Circulating levels and scAT gene expression
of PEDF were not associated in the study subjects, suggesting additional sources for PEDF in addition to or instead
of fat tissue.
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Polycystic ovary syndrome (PCOS), the most prevalent
endocrine disorder in women of reproductive age, af-
fects 9 to 18% of women worldwide, depending on
diagnostic criteria [1]. PCOS has also been recognized
as a metabolic disorder, manifested by abdominal obesity,
insulin resistance, dyslipidemia and hypertension. These
factors seem to increase the risk of cardiovascular
disease and metabolic syndrome in this population
[2-8]. Obesity has a pooled estimated prevalence of
49% among women with PCOS, as shown by a recent
meta-analysis [9].
Pigment epithelium-derived factor (PEDF), a member
of the serine protease inhibitor family, is a pleiotropic
protein known for its antiangiogenic, antioxidant, and
neuroprotective properties [10,11]. Cumulating evidence
suggests that PEDF is associated with adiposity, type 2
diabetes, and the metabolic syndrome [12,13]. Further-
more, PEDF has been shown to be an adipokine (adipo-
cyte-secreted protein) that induces insulin resistance and
plays a role in glucose metabolism [14-18].
Recent studies on circulating PEDF levels have shown
elevated serum PEDF in association with insulin resist-
ance in normal-weight women with PCOS [19], but not
in obese PCOS patients [20]. Therefore, our aim was to
characterize PEDF gene expression in subcutaneous
adipose tissue (scAT) from women with PCOS and
nonhirsute, ovulatory control women, and to determine
circulating levels of PEDF in these groups. We also eval-
uated the association between PEDF features and clin-




This case–control study was carried out with women of
reproductive age seen at the Gynecological Endocrinology
Unit at Hospital de Clínicas de Porto Alegre, Brazil.
Women with a body mass index (BMI) ranging from 18.5
to 39.9 kg/m2 were selected for the study. Twenty-two
hirsute oligo-amenorrheic women (<9 cycles/year), pre-
senting with increased levels of serum testosterone
(>0.8 ng/mL) and/or free androgen index (FAI) (>6.1)
and/or polycystic ovaries in the absence of other dis-
orders causing hirsutism [21,22], were included. A
control group was set up with 14 non-hirsute ovula-
tory women (regular cycles and luteal phase proges-
terone levels higher than 3.8 ng/mL) with normal
androgen levels and normal ovaries on ultrasound,
recruited through public advertisement at the same
Gynecological Endocrinology Unit. None of the women
from either group had received any drugs known to inter-
fere with hormone levels, blood pressure, or meta-
bolic variables for at least 3 months before the study.Women with diabetes, liver or kidney disease, thyroid
dysfunction or pregnancy were excluded.
Twenty-two additional volunteers without laparoscopic
evidence of pelvic disease were recruited for collection of
subcutaneous and omental adipose tissue samples. This
was done to ensure that PEDF gene expression could
be reliably measured in scAT. The study protocol was
approved by the Research and PostGraduate Group of
Hospital de Clinicas de Porto Alegre (GPPG/HCPA)
and the local Ethics Committee, and written informed
consent was obtained from all participants.
Study protocol
Medical interview and physical examination were
performed as previously described [23,24]. Hirsutism
was defined as a modified Ferriman-Gallwey score of 8
or more [25]. Blood pressure (BP) was measured in the
sitting position after a 10-minute rest [26]. Anthropo-
metric measurements included body weight, height,
body mass index (BMI), waist circumference and waist/
hip ratio (WHR) [23,27,28]. Hormonal and metabolic as-
sessment as well as abdominal/transvaginal ultrasound
were performed in all PCOS and control participants
between days 2 and 10 of the menstrual cycle or on any
day if the patient was amenorrheic. Polycystic ovary
appearance (PCO) was defined as previously reported
[5,29]. After an overnight 12-hour fast, blood samples
were drawn from an antecubital vein between 8 a.m. and
10 a.m. for determination of serum PEDF and lipid pro-
file at baseline, and glucose and insulin before and
2 hours after ingestion of 75 g oral anhydrous glucose
(oral glucose tolerance test). Blood samples were also
assessed for measurement of luteinizing hormone
(LH), sex hormone–binding globulin (SHBG) and total
testosterone (TT). Free androgen index was estimated by
dividing TT (nmol/L) by SHBG (nmol/L) × 100. Homeo-
stasis model assessment index to estimate insulin resist-
ance (HOMA-IR) was calculated by multiplying insulin
(mIU/mL) by glucose (mmol/L) and dividing this product
by 22.5 [30]. Low-density lipoprotein (LDL) cholesterol
was estimated indirectly with the Friedewald formula [31].
Biochemical and hormonal assays
Total cholesterol, high-density lipoprotein (HDL) chol-
esterol, triglycerides, and glucose were determined by
colorimetric-enzymatic methods (Siemens Advia System,
Deerfield, IL, USA). Enzyme-linked immunosorbent assay
(Chemicon International, Temecula, CA, USA) was used
to measure total serum PEDF, with a sensitivity (S) of
0.9 ng/mL, intra-assay coefficient of variation (CV) of
<5.3% and interassay CV <16%. As recommended by the
manufacturer, to prevent PEDF from associating with
other circulating proteins that may interfere with quantifi-
cation of total serum concentration of this adipokine,
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centration) for 60 minutes in ice and diluted 450
times in dilution buffer before being applied in dupli-
cate to ELISA plates. Serum insulin (S = 0.2 mIU/mL),
LH (S = 0.1 mIU/mL) and SHBG (S = 0.35 nmol/L)
levels were measured with electrochemiluminescent im-
munoassays (Roche Diagnostics, Mannhein, Germany),
with intra-assay CV <3% and interassay CV <5%. Total
serum TT levels were measured with radioimmunoassay
(Diagnostics Systems Laboratories Inc., Webster, TX),
with S <0.1 ng/mL and CV <9.6%.
Tissue collection
scAT biopsy was performed in all participants (22 PCOS
and 14 control women) to obtain a 250 mg adipose
tissue sample from the periumbilical region. To assess
scAT and omental adipose tissue (omAT), another 22
normal women were recruited and samples were obtained
through laparoscopy. Procedures were performed between
days 2 and 10 of the menstrual cycle, or on any day if the
patient was amenorrheic, by surgeons from the Plastic
Surgery Service at Hospital de Clínicas de Porto Alegre or
at the Human Reproductive Unit of Hospital Fêmina. Adi-
pose tissue fragments were immediately frozen in liquid
nitrogen and stored at −80°C until total RNA isolation.
RNA isolation
Adipose tissue total RNA extraction was carried out in
phenol-guanidine isothiocyanate (Trizol®, Invitrogen™
Life Technologies, Foster City, CA, USA) as previously
described [32,33]. Concentration and quality of total
RNA were assessed using a GeneQuant spectro-photometer
(Pharmacia Biotech, Cambridge, England).
Real-time RT-PCR protocol
Reverse transcription of 1 μg of total RNA into cDNA was
carried out using the Superscript II First-Strand Synthesis
System for RT-PCR (Invitrogen™ Life Technologies, Foster
City, CA, USA), according to manufacturer instructions,
in a PCT-100™ Programmable Thermal Controller (MJ
Research Inc., Watertown, MA, USA). Real-time PCR was
performed in triplicate in a 7500 Fast Real-Time PCR
System thermal cycler with 7500 Fast System Sequence
Detection 1.4 Software (Applied Biosystems, Foster City,
CA, USA). SYBR® Green dye fluorescence was detected by
real-time monitoring experiments [34-36]. Primers were
designed using the Primer Express 3.0 Software for Real-
Time PCR (Applied Biosystems, Foster City, CA, USA),
and acquired from Invitrogen™ Life Technologies (Foster
City, CA, USA). Primer sequences were designed to target
two exons of mRNA with respect to known splice variants
and single-nucleotide polymorphism positions. The for-
ward and reverse primer sequences designed for pigment
epithelium-derived factor (NM_002615.5) were (5′ to 3′)CATCATTCACCGGGCTCTCTAC and GGCCTGGTC
CCATATGACTTTT, respectively. These primers anneal
between residues 463 to 484 (forward) and 654 to 633
(reverse), producing a 192-bp amplicon. mRNA quantita-
tion was normalized to glyceraldehyde-3-phosphate de-
hydrogenase (NM_002046.3). The forward and reverse
GAPDH primer sequences, ACCCACTCCTCCACCTT
TG and CTCTTGTGCTCTTGCTGGG (5′ to 3′), re-
spectively, anneal between residues 970 to 988 and 1,147
to 1,129, resulting in an amplicon of 178 bp. Complemen-
tary DNA samples (0.87 ng/μL) were mixed with a
predetermined forward and reverse primer volume (0.5
and 0.7 μL for PEDF; 0.9 and 0.9 μL for GAPDH) and
12.5 μL of 2X Fast SYBR® Green Master Mix (Applied
Biosystems, Foster City, CA, USA) for a total volume of
25 μL. Protocol conditions consisted of denaturation at
94°C for 2 min followed by 50 cycles (30 sec, 94°C and
30 sec, 60°C). Amplicons produced single sharp peaks
during melting curve analysis.
Data were analyzed by relative quantitation using the
comparative CT method [37]. Validation assays were
performed by amplification of the target and reference
genes, separately, using serial dilutions of an mRNA
sample. Both target and reference mRNAs presented
equal efficiencies of amplification. The ΔΔCT method
calculates changes in gene expression as relative fold
difference between an experimental and calibrator
sample, correcting for nonideal amplification efficien-
cies [38].
Statistical analysis
Data were described as mean ± standard deviation (SD)
or median [interquartile range]. The Wilcoxon two-
related-samples test or the unpaired two-tailed Student’s
t-test was used to compare group means for data with
Gaussian distribution. The Mann–Whitney U test was
used to compare group medians for data with non-
Gaussian distribution. Pearson’s or Spearman’s rank cor-
relation coefficients were calculated between variables
using a two-tailed test for significance. A forward step-
wise multiple regression model was also calculated using
serum PEDF as a dependent variable, and fasting insulin
and TT as independent variables. Log10 transformation
was used to normalize the distribution of non-Gaussian
variables, and these variables were back-transformed
into their original units for presentation. Data were con-
sidered statistically significant at p < 0.05. The Statistical
Package for the Social Sciences v. 18 (SPSS, Chicago, IL)
was used for all statistical analyses.
Results
Figure 1 shows PEDF gene expression in scAT and
omAT from healthy controls (mean age, 33.3 ± 6.4 years).
PEDF mRNA was significantly higher in scAT versus
Figure 1 PEDF gene expression in subcutaneous (scAT) and
omental (omAT) adipose tissue of normal women (n = 22).
Messenger ribonucleic acid (mRNA) was expressed as n-fold-change
difference from the calibrator sample (ΔΔCT method). Values are
expressed as median and interquartile range (lower and upper limit
of the box). p = 0.042 in relation to scAT by Wilcoxon two-related-
samples test.
Table 1 Clinical and hormonal features of women with PCOS
Characteristic Control (n = 14)
Age (years) 25.4 ± 2.4
BMI (kg/m2) 26.9 ± 5.5
Waist circumference (cm) 85.5 ± 9.8
WHR 0.78 ± 0.06
Ferriman-Gallwey score 1 (0–3)
Systolic BP (mmHg) 111 ± 4
Diastolic BP (mmHg) 68 ± 6
Glucose, fasting (mg/dL) 87 ± 6
Glucose, 2 h (mg/dL) 89 ± 13
Insulin, fasting (μIU/mL) 7.8 (4.3-11.2)
Insulin, 2 h (μIU/mL) 56.6 (36.8-94.7)
HOMA-IR 1.8 (1.3-2.8)
Triglycerides (mg/dL) 54 (40–72)
Total cholesterol (mg/dL) 144 ± 35
HDL cholesterol (mg/dL) 48 ± 15
LDL cholesterol (mg/dL) 83 ± 27
LH (mIU/mL) 6.0 (4.0-7.6)
SHBG (nmol/L) 44.9 (35.3-59.3)
Total T (ng/mL) 0.60 (0.47-0.72)
FAI 4.7 (3.8-6.1)
Values are expressed as mean ± SD or median (interquartile range). Statistical differ
body mass index, BP blood pressure, FAI free androgen index, HDL high-density lipo
LH luteinizing hormone, PCOS polycystic ovary syndrome, SHBG sex hormone-bindin
(linear regression).
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change in relation to calibrator sample, p = 0.042).
Most participants were white (86%). The remaining
women were of mixed African and European ancestry.
Concerning clinical presentation, 32% of PCOS patients
were hypertensive and 9% had the metabolic syndrome.
None of the controls had hypertension or metabolic syn-
drome. Age was similar in the PCOS and control groups
(23.9 ± 6.2 vs. 25.4 ± 2.4 years, p = 0.501). Table 1 shows
the clinical and hormonal features of women in the con-
trol and PCOS groups. BMI, waist circumference, WHR,
BP, fasting glucose, HOMA-IR, triglycerides, HDL-
cholesterol and SHBG were similar between the groups.
As expected, hirsutism score, LH and TT were higher in
PCOS (p ≤ 0.02). In addition, PCOS patients presented a
worse metabolic profile, as indicated by higher 2 h
glucose, total and LDL-cholesterol, and fasting and 2 h
insulin levels than controls (p < 0.05). Between-group
differences remained significant after adjustment for
BMI, except for fasting and 2 h insulin.
Mean serum PEDF levels were similar in PCOS and
control women (23.6 ± 11.0 vs. 18.6 ± 7.7 μg/mL, p = 0.622)
(Figure 2A). Median PEDF scAT gene expression did not
differ significantly between PCOS and controls (9.97 [1.52-and controls
PCOS (n = 22) p p*
23.9 ± 6.2 0.334 0.501
30.8 ± 5.9 0.058
90.9 ± 13.7 0.321 0.166
0.83 ± 0.09 0.120 0.079
9 (8–14) 0.003 0.003
117 ± 16 0.096 0.291
75 ± 12 0.178 0.187
88 ± 6 0.555 0.597
117 ± 25 0.007 0.006
12 (8–19) 0.012 0.089
101 (46–175) 0.049 0.110
2.6 (1.8-4.2) 0.083 0.100
77 (48–119) 0.135 0.441
178 ± 40 0.013 0.026
53 ± 9 0.272 0.277
109 ± 35 0.024 0.036
10.9 (6.5-18.6) 0.011 0.020
34.9 (18.4-47.8) 0.173 0.360
1.26 (0.91-1.43) <0.001 0.001
9.4 (6.8-21.3) 0.001 0.101
ences by unpaired two-tailed Student’s t-test or Mann–Whitney U test. BMI
protein, HOMA-IR homeostasis model assessment, LDL low-density lipoprotein,
g globulin, T testosterone, WHR waist to hip ratio. *Adjusted for BMI
Figure 2 Serum PEDF levels and PEDF gene expression. A) Serum PEDF levels and B) PEDF gene expression in subcutaneous adipose tissue
(scAT) in women with PCOS and controls. The number of biopsies analyzed per group appears within parentheses. Values are expressed as median
and interquartile range (lower and upper limit of the box). PCOS: polycystic ovary syndrome. No significant between-group differences in PEDF serum
levels (Student’s t-test). Messenger RNA was expressed as n-fold-change difference from the calibrator sample (ΔΔCT method). No significant
between-group differences in scAT PEDF gene expression (Mann–Whitney U test). Analyses were adjusted for BMI (linear regression).
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calibrator sample, p = 0.509) (Figure 2B). No correlation
was found between circulating PEDF levels and scAT
PEDF gene expression (r = 0.116, p = 0.514). Serum PEDF
correlated positively with BMI and waist circumfer-
ence in both the PCOS and control groups (r = 0.556
and r = 0.506, respectively, p ≤ 0.004). In women with PCOS,
serum PEDF also correlated with WHR, triglycerides, fasting
insulin and HOMA-IR (r = 0.537, r = 0.473, r = 0.536
and r = 0.533, respectively, p ≤ 0.026). Multiple linear
regression analysis revealed that insulin contributed
positively and significantly to serum PEDF, independ-
ently of total testosterone, only in the PCOS group
(Tables 2 and 3). Concerning the components of the
metabolic syndrome, waist circumference greater than
88 cm was a significant independent predictor of serum
PEDF in this study group, explaining 35% (p = 0.001) of
variance in plasma PEDF concentrations.
Discussion
In the present study, serum PEDF levels and scAT gene
expression did not differ between women with PCOS
and age- and BMI-matched controls. The decision to
measure PEDF gene expression in scAT was based on
the finding that PEDF expression was higher in scATTable 2 Model-fitting results of stepwise regression for
serum PEDF vs. significantly correlated variables for
control women
Serum PEDF (ug/ml) vs.
independent variables
Coefficient ± SE β p
Fasting insulin 6.853 ± 8.731 0.236 0.451
Total testosterone 9.346 ± 13.197 0.213 0.495
r2 = 0.114.
β standardized regression coefficients. Values for fasting insulin and total
testosterone were log10-transformed.than in omAT, as recently reported [39]. An advantage
of using subcutaneous fat is that sample collection is less
invasive than for omental fat.
One recent study reported that PEDF was related to
obesity, but not to subcutaneous adiposity or insulin re-
sistance, in obese women with PCOS [20]. On the one
hand, this supports our hypothesis that PEDF does not
originate from scAT. We observed that gene expression
and circulating levels of scAT were not correlated in ei-
ther PCOS or control women. No other significant cor-
relations were found between subcutaneous PEDF
expression and clinical, hormonal or metabolic variables,
indicating that scAT production of PEDF is not the main
determinant of serum PEDF concentrations. Moreno-
Navarrete et al. [39] have demonstrated that liver, but
not adipose tissue, might be the source of increased cir-
culating PEDF, associated with insulin resistance, as pre-
viously proposed by other authors [16,17].
On the other hand, the findings of Joham et al. [20] in-
dicate that PEDF does not play a causal role in the
development of insulin resistance, strengthening the no-
tion that women with PCOS have an intrinsic insulin-
related dysfunction that might be exacerbated by, but
not attributed to, obesity, as previously thought [40]. In
our PCOS group, circulating PEDF levels were alsoTable 3 Model-fitting results of stepwise regression for
serum PEDF vs. significantly correlated variables for
PCOS women
Serum PEDF (ug/ml) vs.
independent variables
Coefficient ± SE β p
Fasting insulin 22.662 ± 9.379 0.565 0.027
Total testosterone −4.590 ± 13.509 −0.080 0.738
r2 = 0.279.
β standardized regression coefficients. Values for fasting insulin and total
testosterone were log10-transformed.
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positive correlations with triglycerides, fasting insulin
and HOMA-IR. Data regarding the regulation of PEDF
in women with PCOS, as well as in general populations
are lacking. Recent work has implicated PEDF in the in-
ducement of lipolysis, promoting lipid accumulation in
muscle and liver and reducing fatty acid oxidation that
was associated with insulin resistance [14]. In the gen-
eral non-diabetic population, circulating PEDF has been
related to aspects of the metabolic syndrome, including
obesity, triglyceride levels, diastolic blood pressure, glu-
cose, and insulin levels [12,17,41]. A few studies in pa-
tients with type 2 diabetes have demonstrated that PEDF
levels were not only associated with the components of
the metabolic syndrome, but also higher in proportion
to the accumulation of the number of the components
[13,16]. Few data are available in the literature
concerning PEDF gene expression and metabolic syn-
drome or their isolated components. However,
Nakamura et al. [16] showed that PEDF mRNA levels in
cultured adipocytes were increased in parallel to the
BMI values of subjects from whom adipocytes were de-
rived, especially in omental adipocytes. In addition,
Moreno-Navarrete et al. [39] reported that scAT PEDF
gene expression was decreased in subjects with type 2
diabetes and did not change significantly after weight
loss.
Conversely, a previous study has shown that PEDF
serum levels were elevated in association with insulin
resistance in normal-weight PCOS women when com-
pared to BMI-matched controls [19]. While in that
study, as in ours, serum PEDF levels were correlated
with BMI in PCOS patients—suggesting that obese
women with PCOS are also likely to have increased
levels of PEDF—no significant elevation of PEDF was
found in overweight/obese women with PCOS. However,
in the study by Yang et al., only five women with PCOS
were obese; therefore, the findings in these women were
not conclusive. In the present study, the comparison
between PCOS and control women covering a wide
range of BMIs showed similar BMI-adjusted PEDF
serum levels.
It is also interesting to note that, while there is evi-
dence that circulating PEDF levels are higher in men
than in women [12,17,41,42], and despite the higher TT
found in our patients with PCOS as compared with con-
trol women, the testosterone-independent association
between PEDF and insulin levels observed herein sug-
gests that androgen excess does not play an essential
role in PEDF circulating levels.
Limitations of the present study were the relatively
small sample size, which precluded stratification of
groups by BMI for comparison, and the lack of assess-
ment of PEDF levels on different days of the menstrualcycle in control women. Therefore, further studies are
required to investigate the associations between PEDF
and clinical phenotype and pro-inflammatory markers in
normal-weight versus obese women with PCOS, as well
as to better characterize PEDF secretion over the course
of the menstrual cycle.
Conclusions
Serum levels and scAT gene expression of PEDF were
similar in women with PCOS and age- and BMI-
matched healthy controls, and were associated with
metabolic risk factors. Furthermore, circulating levels of
PEDF were not associated with subcutaneous adipose
tissue gene expression in the study subjects, suggesting
the existence of other sources for PEDF.
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